8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  02/02/2010

TRIMERIS, INC.

(Exact name of registrant as specified in its charter)

Commission File Number:  0-23155

DE	56-1808663
(State or other jurisdiction of	(IRS Employer
incorporation)	Identification No.)

2530 Meridian Parkway, 2nd Floor, Research Triangle Park, NC 27713

(Address of principal executive offices, including zip code)

(919) 806-4682

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02.    Results of Operations and Financial Condition

On February 2, 2010, Trimeris, Inc. (the "Company") issued a press release announcing sales of FUZEON for the fourth quarter and year ended December 31, 2010. A copy of the press release is attached hereto as Exhibit 99.1.

The information under this Item 2.02 and including Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01.    Financial Statements and Exhibits

(d) Exhibits

99.1   Press release dated February 2, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		TRIMERIS, INC.
Date: February 03, 2010	By:	/s/    Michael A. Alrutz
		Michael A. Alrutz
		General Counsel

EXHIBIT INDEX

Exhibit No.	Description
EX-99.1	Press release dated February 2, 2010

EX-99.1

Exhibit 99.1

Contacts:

Andrew Graham

Chief Financial Officer

Trimeris, Inc.

(919) 806-4682

Trimeris Reports Fourth Quarter 2009 FUZEON Sales Results

DURHAM, N.C. - February 2, 2010 - Trimeris, Inc. (Nasdaq: TRMS) ("Trimeris") today announced worldwide net sales of FUZEON for the fourth quarter of 2009 were $25.5 million, down 37 percent from $40.5 million in the fourth quarter of 2008, and down 14 percent from $29.8 million in the third quarter of 2009. Net sales of FUZEON in the U.S. and Canada for the fourth quarter of 2009 were $9.0 million, down 44 percent from $16.1 million in the fourth quarter of 2008, and down 13 percent from $10.4 million in the third quarter of 2009. Net sales of FUZEON outside the U.S. and Canada for the fourth quarter of 2009 were $16.5 million, down 32 percent from $24.4 million in the fourth quarter of 2008, and down 15 percent from $19.4 million in the third quarter of 2009. All sales of FUZEON are recorded by F. Hoffmann-La Roche Ltd., Trimeris' collaborative partner.

Net sales of FUZEON for 2009 were $112.2 million, down 33 percent from $167.0 million in 2008. Net sales of FUZEON in the U.S. and Canada for 2009 were $39.1 million, down 39 percent from $64.2 million in 2008. Net sales of FUZEON outside the U.S. and Canada for 2009 were $73.1 million, down 29 percent from $102.8 million in 2008.

Trimeris plans to release its complete financial results for 2009 in early March 2010.

Net FUZEON Sales

The table below presents net FUZEON sales by quarter beginning in the first quarter of 2007:

(millions)	2009
	Q1	Q2	Q3	Q4	Total
U.S/Canada Net Sales	$10.0	$9.7	$10.4	$9.0	$39.1
Ex. U.S/Canada Net Sales	17.8	19.4	19.4	16.5	73.1
Global Net Sales	$27.8	$29.1	$29.8	$25.5	$112.2
Brazil Purchase*	$7.1	$8.0	$7.8	$7.6	$30.4
	2008
	Q1	Q2	Q3	Q4	Total
U.S/Canada Net Sales	$17.0	$16.1	$14.9	$16.1	$64.2
Ex. U.S/Canada Net Sales	25.7	22.2	30.6	24.4	102.8
Global Net Sales	$42.7	$38.3	$45.5	$40.5	$167.0
Brazil Purchase*	-	-	$11.4	$10.0	$21.4
	2007
	Q1	Q2	Q3	Q4	Total
U.S/Canada Net Sales	$29.3	$32.9	$30.6	$31.5	$124.3
Ex. U.S/Canada Net Sales	35.0	29.2	43.3	35.0	142.5
Global Net Sales	$64.3	$62.0	$73.9	$66.5	$266.8
Brazil Purchase*	$6.0	-	$13.8	$7.3	$27.1

(numbers may not add due to rounding)

*included in Ex. U.S/Canada Net Sales and Global Net Sales

About Trimeris, Inc.

Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. FUZEON, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about Trimeris, please visit the Company's website at http://www.trimeris.com.

Trimeris Safe Harbor Statement

This document and any attachments may contain forward-looking information about the Company's financial results and business prospects that involve substantial risks and uncertainties. These statements can be identified by the fact that they use words such as "expect," "project," "intend," "plan," "believe" and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially are the following: there is uncertainty regarding the success of research and development activities, regulatory authorizations and product commercializations; we are dependent on third parties for the sale, marketing and distribution of our drug candidates; the market for HIV therapeutics is very competitive with regular new product entries that could affect the sales of our products; the results of our previous clinical trials are not necessarily indicative of future clinical trials; and our drug candidates are based upon novel technology, are difficult an d expensive to manufacture and may cause unexpected side effects. For a detailed description of these factors, see Trimeris' Form 10-K filed with the Securities and Exchange Commission on March 13, 2009, and its subsequent periodic reports filed with the SEC.

--end-